advance ovarian cancer
Conditions
Interventions
none:Apatinib mesylate 500mg/day
B:Apatinib mesylate,500 mg/day,continuous
Sponsors
The 1st Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Patients are pathologically diagnosed with advanced ovarian cancer which can be measured; 3. Patients had undergone and sensitived with chemotherapy TP ; 4. ECOG score 0-2 score; 5. The expected survival is longer than 3 months; 6. blood tests must meet with the standards that they dont receive any blood transfusion,blood products,G-CSF or other hematopoietic unused stimulating factor within 14 days: (1) HB=90 g/L; (2) WBC= 3.5×10^9; LANC=1.5×10^9/L; (3) PLT=80×10^9/L; 7. Standards of biochemical tests: (1) TBIL<1.5*ULN; (2) ALT and AST<40U/L; (3) Serum Cr or creatinine clearance rate is in the normal detection range.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women; 2. Suffering from high blood pressure or can not fall within the normal range by antihypertensive medications (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg), class I myocardial ischemia, myocardial infarction, arrhythmias (including QT interval of =440 ms) or class II heart failure; 3. coagulopathy (INR> 1.5 or prothrombin time (PT)> ULN + 4 seconds or APTT> 1.5 ULN); having a tendency to bleed; receiving thrombolytic or anticoagulant therapy; 4. participated in clinical trials of other drugs within four weeks; 5. Received EGFR inhibitors such as sorafenib, sunitinib or other treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS (progression-free survival); | — |
Countries
China
Contacts
Public ContactYuan Zhongfu
The 1st Affiliated Hospital of Zhengzhou University
Outcome results
None listed